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Abstract: Schizophrenia is a psychotic disorder that exists at the more extreme end of a spectrum of
diseases, and significantly affects daily functioning. Cardiovascular adverse effects of antipsychotic
medications are well known, and include changes in blood pressure and arrhythmias. Sudden cardiac
death is the leading cause of death worldwide, and antipsychotic medications are associated with
numerous cardiac side effects. A possible link exists between antipsychotic medications and sudden
cardiac death. Common prescribing patterns that may influence cardiovascular events include
the use of multiple antipsychotics and/or additional drugs commonly prescribed to patients on
antipsychotics. The results of this review reflect an association between antipsychotic drugs and
increased risk of ventricular arrhythmias and sudden cardiac death by iatrogenic prolongation of
the QTc interval. QTc prolongation and sudden cardiac death exist in patients taking antipsychotic
monotherapy. The risk increases for the concomitant use of specific drugs that prolong the QTc
interval, such as opioids, antibiotics, and illicit drugs. However, evidence suggests that QTc intervals
may not adequately predict sudden cardiac death. In considering the findings of this narrative
review, we conclude that it is unclear whether there is a precise association between antipsychotic
polypharmacy and sudden cardiac death with QTc interval changes. The present narrative review
warrants further research on this important potential association.
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1. Introduction
Schizophrenia is a psychotic disorder that exists at the more severe end of a spectrum
of diseases, and is characterized by positive symptoms, such as hallucinations or delusions;
negative symptoms, such as blunted affect and anhedonia; and cognitive impairments
that grossly affect daily functioning [1–3]. Altered dopamine, glutamate, and serotonin
signaling in the corpus striatum, hippocampus, midbrain, and prefrontal cortex have
been indicated in the process of psychosis [4]. According to the dopamine hypothesis of
schizophrenia, the positive symptoms of the illness, otherwise known as hallucinations and
delusions, are due to the excessive activation of D2 receptors in the mesolimbic pathway [5].
As such, antipsychotic treatment options have some degree of action at the D2 receptor,
primarily antagonism [2,4]. Conversely, low levels of dopamine in the nigrostriatal pathway
are thought to cause motor symptoms via the extrapyramidal system, and low levels of
dopamine in the mesocortical pathway are thought to cause the negative symptoms of
schizophrenia, such as avolition and flat facies [5].
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Antipsychotics can also antagonize alpha-adrenergic receptors. The antagonization of
the alpha-1 receptors is thought to improve the positive symptoms, and the antagonization of the alpha-2 receptors helps relieve both the negative and cognitive symptoms [6].
However, this can have cardiac-related adverse effects, such as tachycardia and orthostatic
hypotension [7]. Antipsychotics can also antagonize cholinergic receptors, such as the
muscarinic receptors, leading to an elevated resting heart rate, QT prolongation, and the
induction of polymorphic ventricular tachycardia, also called torsade de pointes [7,8]. Over
60 antipsychotic medications have been developed over time for the symptomatic treatment
of psychosis, 20 of which are available for use in the United States [2,4]. Choosing which
antipsychotic medication to use can be challenging [2].
The adverse effects (AE) of antipsychotic medications include extrapyramidal, metabolic,
sedative, and cardiovascular effects, such as changes in blood pressure and arrhythmias [2].
Arrhythmias can lead to a condition known as sudden cardiac death (SCD), and the most
common of these is ventricular fibrillation [9]. Hypertension can lead to arrhythmias; more
importantly, chronic hypertension can lead to ventricular arrhythmias, such as ventricular
fibrillation [10]. Hypertension causes the hypertrophy of the cardiac muscles, the proliferation of fibrous tissue, and increased intercellular coupling [11]. This leads to dysfunctional
electrical properties in the cardiac tissues and the propensity for various arrhythmias [11].
The most common of these arrhythmias is atrial fibrillation [12]. Chronic hypertension can
lead to left ventricular hypertrophy and ultimately heart failure, leading to supraventricular
arrhythmias and ventricular arrhythmias [12].
Age and the onset of menopause can lead to an increase in antipsychotic adverse effects.
With the onset of menopause, estrogen levels drop, which studies have shown to lead to
the worsening of hallucinations and delusions during this time [13]. This may necessitate
the need for increased dosages of antipsychotic doses, which can lead to increased adverse
effects. Age also plays a role in the probability of adverse effects, especially cardiac adverse
effects. The elderly often also have cardiovascular diseases and other comorbid conditions,
and thus may be more likely to be taking multiple medications, making polypharmacy an
issue [14].
Medications blocking alpha-1-adrenergic and beta-adrenergic receptors help protect
against ventricular arrhythmias. However, activating the cardiac D1 receptors can trigger
these arrhythmias [15,16]. SCD can be defined as abrupt, unexpected death due to cardiac
causes within an hour of symptoms starting, if witnessed, or one day if not [9,17]. SCD is
generally related to structural heart diseases, such as ischemic heart disease and hypertrophic cardiomyopathy, or to electrophysiologic conditions, such as long QT syndrome
and ventricular fibrillation [9,17]. As sudden cardiac death is the leading cause of death
worldwide [9], and antipsychotic medications have known cardiac side effects [2], a review
of the possible link between the use of antipsychotic medications and sudden cardiac death
is worthwhile. This is especially important as polypharmacy with multiple antipsychotics
or multiple other medications is common among those taking antipsychotics. The aim of
this narrative review, therefore, is to investigate these relationships. Manuscripts were
pulled from PubMed over the time span of 2000–2021, and included if they were in English.
2. Cardiac Issues and Antipsychotics
Antipsychotics are highly effective drugs used to manage psychosis caused by schizophrenia and other psychiatric disorders. However, the use of antipsychotics has been associated with cardiac adverse effects, including QTc prolongation, life-threatening arrhythmias,
and sudden cardiac death [18]. Related to this association, a risk–benefit assessment into the
role of antipsychotics is warranted, in conjunction with other antipsychotics and additional
drugs, especially in high-risk patients [18,19].
2.1. QTc Interval
Prolonging the QTc interval on an electrocardiograph (ECG) can predispose individuals to life-threatening ventricular arrhythmia and sudden cardiac death [20]. The QTc
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interval is the QT interval corrected for heart rate. The association between antipsychotic
drugs and increased risk of ventricular arrhythmias and sudden cardiac death is likely
explained by iatrogenic prolongation of the QTc interval. The QT interval is a measurement
of the conduction time of ventricular depolarization to the end of repolarization, and it
represents the time between ventricular depolarization and repolarization. However, the
QT interval also depends on heart rate, and is therefore corrected using various formulas
√
√
(i.e., Fridericia formula, QTc = QT/3 RR; Bazett formula, QTc = QT/ RR) [21].
The normal upper limit for QTc interval is 450 ms in men, 460 ms in women, and
440 ms in children [19,21–23]. Clinically significant QTc interval prolongation is a QTc
>500 ms or a rise in QTc >60 ms above baseline. This degree of prolongation carries a risk
of torsade de pointes, a potentially fatal ventricular arrhythmia [19,21,22]. While many
antipsychotics are associated with QTc prolongation, QTc prolongation to this clinically
significant threshold is relatively uncommon, and the incidence of torsade de pointes is
even rarer [19,21].
While QTc is a well-accepted marker of the risk of torsade de pointes, the degree of
QTc prolongation can only modestly predict this risk of torsade de pointes. The degree of
QTc prolongation produced by one drug may carry a different risk than the same degree of
QTc prolongation produced by another drug [19,22]. For example, amiodarone can cause
significant QTc prolongation (>13 ms), but rarely causes torsade de pointes [24]. However,
haloperidol causes a QTc prolongation of <8 ms, but has been linked to many cases of
torsade de pointes and sudden death [19].
2.2. Risk Factors
While the risk of torsade de pointes is challenging to predict with a QTc interval, considering several factors that increase the risk of QTc prolongation and torsade de pointes can
offer insight into whether QTc-prolonging medication is appropriate for use. A thorough
assessment of these risk factors is recommended before using an antipsychotic medication [19]. The risk of QTc prolongation increases with preexisting heart diseases, including
congenital long QT syndrome, coronary artery disease, congestive heart failure, myocarditis, and hypertension. Non-cardiac conditions are also associated with an increased risk
of QTc prolongation, including subarachnoid hemorrhage, cerebrovascular disease, hypothyroidism, hypokalemia, hypomagnesemia, hypocalcemia, obesity, and polypharmacy.
Additionally, women, and those over 65 years of age, are at a higher risk [19–21,23].
2.3. Typical Antipsychotics
Thioridazine is a typical antipsychotic, and exhibits the greatest QTc prolongation and
sudden death risk. Thioridazine is a potent blocker of rapid delayed rectifier (IKr) channels,
and results in a mean increase in QTc of 30–35 ms, since it delays repolarization [19,23,25].
By slowing repolarization, spontaneous early depolarizations can generate and induce
asynchronous cardiac tissue excitation, increasing the risk of torsade de pointes [21]. In
addition to significant QTc prolongation, thioridazine is also associated with sudden
cardiac death. Under the brand name Mellaril, thioridazine was once frequently used to
treat schizophrenia. It has now been discontinued, as of 2005, in the United States due to
the high risk of cardiac arrhythmia and sudden cardiac death [18,26]. It is, however, still
available in the generic version.
Haloperidol is another typical antipsychotic; it is associated with the highest risk of
sudden cardiac death, despite a mean QTc prolongation of 4–7 ms [19,21,23]. It causes
QTc prolongation by IKr channels, but it is less potent in its inhibition than thioridazine.
Haloperidol is thought to have additional actions on cardiac ionic currents, which may
explain the discrepancy between the high risk of sudden cardiac death despite minimal
QTc prolongation [21]. Haloperidol has been found to moderately inhibit the L-type
calcium channels in the heart, shortening the action potential [27]. This shortened action
potential can predispose the patient to arrhythmias. The association between haloperidol
and ventricular arrhythmias is more significant when administered intravenously than
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orally [20]. Haloperidol remains an effective treatment for schizophrenia and psychosis.
Still, the FDA recommends regular ECG monitoring for QTc prolongation and arrhythmias,
especially for IV haloperidol and one-time IV doses ≥2 mg [19]. Figure 1 shows this
interaction.

Figure 1. Haldol blocks the L-type calcium channel in the cardiac muscles, which prolongs the cardiac
action potential. This prolongation can lead to ventricular arrythmias, which may be lethal.

2.4. Atypical Antipsychotics
Ziprasidone is an atypical antipsychotic, and exhibits the most significant degree
of QTc prolongation, but with very few reported cases of torsade de pointes or sudden
cardiac death. Only 0.06% of patients using ziprasidone exhibit QTc >500 ms, and the one
case of sudden cardiac death attributed to ziprasidone involved a patient that also had
polypharmacy and electrolyte imbalance [19]. Ziprasidone has a mean QTc prolongation
of 9.6–20.3 ms [20,21,23]. It causes QTc prolongation via the blockade of IKr channels,
with a similar potency as haloperidol [21]. Ziprasidone remains an effective treatment for
schizophrenia and bipolar disorder [18].
Olanzapine is another atypical antipsychotic used for the treatment of schizophrenia.
There are no reported cases of torsade de pointes attributed to olanzapine, but there have
been a few cases of sudden cardiac death [18,23,26]. It has a mean QTc increase of 6.8 ms,
and causes this prolongation via actions on IKr channels [21]. While the risk of torsade
de pointes and sudden cardiac death caused by olanzapine is relatively low, olanzapine
is strongly associated with metabolic syndrome. It can cause weight gain, dyslipidemia,
hyperglycemia, and insulin resistance, leading to cardiovascular disease [28].
Risperidone is another atypical antipsychotic used to treat schizophrenia, and has been
linked to torsade de pointes and sudden cardiac death. Risperidone has a mean QTc increase
of 9.1 ms, and causes QTc prolongation via actions on IKr channels, with a similar potency
as haloperidol [16]. Still, the risk is much lower than haloperidol and thioridazine [13,18,21].
Table 1 summarizes the antipsychotics discussed here, the associated cardiac events, and
the mechanism by which these events could happen.
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Table 1. Cardiac Issues and Antipsychotics.
Antipsychotic

Class

Cardiac Issues

Mechanism

Thioridazine

First Generation

Highest risk of QTc
prolongation
Increase of 30–35 ms

Very potent blocker of
IKr channels, resulting in
delayed repolarization

Haloperidol

First Generation

QTc prolongation of
4–7 ms
Still has the highest
risk of sudden cardiac
death

Can block IKr channels,
but it is a less potent
inhibitor than
thioridazine
Can block L-type calcium
channels, causing a
shortening of the action
potential

Ziprasidone

Second Generation

Mean QTc
prolongation of
9.6–20.3 ms

Blockade of IKr channels
with a similar potency as
haloperidol

Olanzapine

Second Generation

Mean QTc increase of
6.8 ms

Actions on IKr channels

Risperidone

Second Generation

Mean QTc increase of
9.1 ms

Actions on IKr channels
with a similar potency as
haloperidol

3. Interactions between Antipsychotics and Non-Psychotropic Medications
The use of antipsychotics with other medications can significantly increase the risk
of cardiac adverse effects (AEs), including sudden cardiac death [29]. As a result, it is
essential to carefully review all medicines and medical histories for drugs with cardiac
adverse effects. Commonly used medications with cardiac AEs are discussed below.
3.1. Opioids
Opioids are commonly used analgesic agents that bind to opioid-specific receptors on
neuronal cell membranes to inhibit the transmission of pain signals. All opioids can cause
vasodilation and bradycardia, resulting in hypotension, edema, or syncope. However,
opioids alone will not alter cardiac function, except for meperidine. Meperidine can
significantly decrease cardiac output by depressing myocardial contractility [30].
Some opioids can prolong the QTc interval, which increases the risk of ventricular
arrhythmias and sudden cardiac death [30]. Methadone is the opioid with the most
significant effect on the QTc interval [30]. It blocks the delayed rectifier potassium channels
(IKr) encoded by the human ether-à-go-go-related gene (hERG) to delay repolarization [31].
Methadone can cause QT prolongation in a dose-dependent manner [32]. Methadoneinduced torsade de pointes cases have been reported in patients receiving high doses
(>200 mg/day), or even following recent dose increases [32]. However, the incidence of
severe QTc prolongation in individuals taking methadone is relatively low, at 6.0%; this
risk increases if other risk factors are present, including chronic use, female sex, advanced
age, congestive heart failure, and concomitant QTc-prolonging medication use [33].
Buprenorphine has a less profound effect on the QTc interval than methadone, and
has little impact on IKr channels [31]. It has been suggested that buprenorphine is the
safer option for treating opioid use disorder in heroin users and those with, or that have
experienced, methadone-induced torsade de pointes [32]. However, due to unknown mechanisms, high-dose transdermal buprenorphine can significantly increase QTc interval [34].
Additionally, buprenorphine can substantially prolong the QTc interval when combined
with antiretroviral agents [35].
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3.2. Antibiotics
Azithromycin is a macrolide antibiotic used to treat various infections, including
respiratory tract infections, urinary tract infections, and sexually transmitted diseases.
Azithromycin is thought to cause QTc prolongation by blocking IKr channels, which regulate the outward flow of potassium ions during repolarization [36]. In a study comparing
the incidence of severe cardiac arrhythmias and all-cause mortality in US veterans taking
azithromycin vs. amoxicillin, azithromycin was associated with a 1.48-fold increased risk
of death, and a 1.77-fold increased risk of severe cardiac arrhythmia, during the first five
days of treatment. However, this study is limited by potential bias, as the patients prescribed azithromycin may have had more serious infections than the patients prescribed
amoxicillin [37]. Additionally, clinical trials in healthy individuals taking azithromycin
did not prolong QTc interval [38]. Still, a meta-analysis investigating cardiovascular risk
associated with macrolides demonstrated an increased risk of sudden death and ventricular
arrhythmia associated with azithromycin [39].
Similarly, levofloxacin is a commonly used antibiotic belonging to the fluoroquinolone
class, which is thought to cause QTc prolongation by a similar mechanism as azithromycin.
In the same study comparing the incidence of AEs in levofloxacin to amoxicillin, levofloxacin was associated with a 2.43-fold increased risk of serious cardiac arrhythmia and a
2.49-fold increased risk of death during treatment days 1–10 when compared to amoxicillin.
The same potential bias also limits this study, since patients prescribed levofloxacin may
have had more serious infections than patients prescribed amoxicillin [37]. Additionally,
multiple clinical trials in healthy individuals taking levofloxacin did not demonstrate QTc
prolongation [40,41].
In addition to QTc prolongation, the association of fluoroquinolones and macrolides
with heart failure has also been studied. A randomized cohort study assessing cardiac
outcomes in patients taking macrolides, fluoroquinolones, or beta-lactams for communityacquired pneumonia found that levofloxacin and moxifloxacin had a lower risk of heart
failure compared to beta-lactam monotherapy [42]. Erythromycin, a macrolide antibiotic,
was associated with the highest risk of heart failure; as a hepatic CYP 3A4 isozyme inhibitor,
erythromycin can also increase the risk of sudden cardiac death [42,43]. This is an important hepatic enzyme responsible for the metabolism of 50% of available drugs [44]. The
inhibition of CYP 3A4 blocks the metabolism of many antipsychotics, and many other medications, allowing them to be present longer to exert their effects on the body. It is important
to know that there are polymorphisms among CYP enzymes making the metabolizing of
medications either faster or slower in patients with these particular polymorphisms [45].
This should be noted when prescribing medications that work on the CYP3A4 enzyme.
The recent development of pharmacogenetic interventions may help clinicians identify
these polymorphisms in patients and, therefore, avoid the side effects caused by them or
by any other drugs that affect the metabolism of drugs using these pathways [46]. These
interventions are not widely used at this time; however, they do offer an exciting avenue
for research and possible clinical interventions in the future.
3.3. Other Antimicrobials
Chloroquine and hydroxychloroquine are antimalarial agents that have also been
used to treat autoimmune diseases, such as rheumatoid arthritis (RA) and systemic lupus
erythematosus (SLE). However, multiple cardiac complications have been described in
association with chloroquine and hydroxychloroquine use, including increased risk of
QTc prolongation, torsade de pointes, heart blocks, and cardiomyopathy. Populations at
increased risk for cardiac events when taking chloroquine and hydroxychloroquine include
the female sex, advanced age, NSAID users, and SLE patients [47].
Highly active antiretroviral therapy (HAART) is a medication regimen used to treat HIV,
and commonly includes at least three antiretrovirals—protease inhibitors, non-nucleoside
reverse transcriptase inhibitors, and nucleoside reverse transcriptase inhibitors. Treatment with HAART is associated with a risk of QTc prolongation, likely due to protease
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inhibitors [35]. Protease inhibitors have been associated with IKr channel inhibition, leading
to QTc prolongation [48]. The use of HIV medications in the presence of risk factors carries
a greater risk of QTc prolongation. Using the HAART regimen with buprenorphine, which
has a minimal effect on QTc prolongation in isolation, can cause a statistically significant
increase in QTc prolongation [35]. Some studies, however, have noted that other factors,
such as age, gender, and other comorbidities, may be responsible for the QTc prolongation
and adverse cardiac events seen in those using HAART, especially regarding protease
inhibitors [49]. It is important to note that ritonavir, a protease inhibitor used in HAART,
is also a CYP 3A4 inhibitor [44]. As stated in a previous section on antibiotics, inhibition
of this enzyme can lead to the decreased metabolization of some medications, including
some antipsychotics. This can lead to the drug being present in the body for a longer time
duration, prolonging the exertion of its effects.
3.4. Illicit Drugs
Antipsychotic use in people that also use illicit drugs is common, and the possible
AEs should be examined. Cocaine is associated with multiple cardiovascular complications, including myocardial infarction, cardiac arrhythmias, aortic dissection, stroke, and
sudden cardiac death [50]. Cocaine is a dopamine and norepinephrine reuptake inhibitor
that increases sympathetic activation, leading to coronary vasoconstriction, tachycardia,
and hypertension. It also promotes platelet aggregation, leading to thrombus formation,
accelerated atherosclerosis, left ventricular hypertrophy, and stroke [51].
3,4-methylenedioxymethamphetamine (MDMA or “ecstasy”) is a serotonin agonist
and a dopamine and norepinephrine reuptake inhibitor that causes sympathetic hyperstimulation [51]. Repeated use of MDMA causes left ventricular dilation and diastolic
dysfunction, resulting in cardiomyopathy [50]. MDMA can also cause myocardial infarction, QT prolongation, arrhythmia, and sudden cardiac death [51].
Synthetic cannabinoids act on the endocannabinoid system, which has significant roles
in cognitive processes, memory, motor control, pain sensation, and appetite. This drug
can cause various adverse effects, including hypertension or hypotension, bradycardia or
tachycardia, agitation, psychosis, nausea, seizures, and vomiting. It can also significantly
impact the heart’s supraventricular and ventricular conduction system, resulting in arrhythmias. Supraventricular arrhythmias associated with synthetic cannabinoids include
sinus tachycardia, atrial fibrillation, sinus bradycardia, supraventricular tachycardia, and
asystole. Ventricular arrhythmias associated with synthetic cannabinoid use include left
bundle branch blocks, QT prolongation, atrioventricular block, and ventricular fibrillation.
The arrhythmia mechanism is poorly understood, but is dose-dependent and involves
multiple ionic currents [52].
4. Polypharmacy
Patients that take antipsychotic medications, mainly those with schizophrenia, have
increased mortality compared to the general population, with a life expectancy 10–20
years shorter than people without schizophrenia [53,54]. Reasons for this difference are
not certain, but higher rates of suicide, drug and alcohol use, and smoking are likely
contributors [53]. Increased mortality from cardiovascular disease, obesity-related cancers,
diabetes, and COPD can also be seen in people with schizophrenia [53]. With antipsychotic
medications having known metabolic and cardiovascular side effects, much interest has
been shown in investigating the use of polypharmacy in treating schizophrenia and its
impact on mortality [53–57].
Polypharmacy can be defined as the simultaneous use of more than one medication,
and having a complex dosing schedule for the medications [53–56]. The use of multiple
antipsychotic medications is considered inadvisable for several reasons, most of them
regarding lack of adequate evidence to support the safety and efficacy of such treatment
regimens [53–57]. However, that does not mean that there is sufficient evidence to indicate that polypharmacy is less efficacious or more dangerous than monotherapy. Newer
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observational studies have found no significant difference in mortality between patients
on polypharmacy vs. those on monotherapy [53–57]. In general, the research on safety
and efficacy is inconclusive, with some studies showing statistically significant results and
others showing contradictory results [53–57]. It is to be noted that these studies were a mix
of case–control and cohort studies, and not randomized controlled trials.
Several studies have investigated the safety of antipsychotic polypharmacy. Two
population-based nested case–control studies, one performed in China and the other
in Denmark, studied the possibility of polypharmacy increasing mortality from natural
causes [53,54]. Both studies concluded that concurrent antipsychotic medication use did
not increase mortality from natural causes compared to monotherapy [53,54]. Another
study attempted to investigate the safety of long-term (six months or more) antipsychotic
polypharmacy use by comparing mortality to that of long-term monotherapy [57]. While
their results did show a slight increase in all-cause mortality in the long-term polypharmacy
group, the results were not statistically significant [57]. Finally, to investigate cardiovascular
risks associated with polypharmacy, a study compared ECGs among patients treated with
either monotherapy or polypharmacy [58]. Of note, in this study, QTc intervals were
significantly increased for women on antipsychotic polypharmacy compared to those
receiving monotherapy treatment [58]. However, this study was limited by its small sample
size of 65 and the use of two different ECG machines [58]. This study did not account
for differences in QTc interval effects among specific medications [58]. The four studies
discussed here state that their results contradict previous studies, and that a solid conclusion
cannot be inferred [53,54,57,58].
One study explored the efficacy of antipsychotic polypharmacy; it followed 17,255 patients with psychogenic illnesses and compared the rates of unplanned hospital admissions,
emergency department visits, and mortality between patients on monotherapy vs. those
treated with polypharmacy [56]. The authors concluded no differences in outcomes among
patients treated with polypharmacy vs. those on monotherapy and, thus, suggested that
the efficacy of the two treatment options may be similar [56].
Patients may be on multiple antipsychotics for various reasons. For most prescribers,
the use of polypharmacy is primarily centered around the treatment of patients with
symptoms that are difficult to control with monotherapy alone [55,56]. Another reason
patients could be placed on more than one antipsychotic is the brief instance of bridging
between two different monotherapies. However, one study showed that less than half of the
patients intended for bridging ever stopped taking the first drug [56]. Unfortunately, some
patients were started on polypharmacy because their providers considered monotherapy
ineffective, despite not using it at the recommended dose [56]. A possible advantage
of antipsychotic polypharmacy is the prolonged time to discontinuation compared to
monotherapy [56]. However, polypharmacy can result in dosages of medications that are
far higher than recommended and, subsequently, increase the risk of dose-dependent side
effects and drug–drug interactions [56]. With conflicting results and uncertain outcomes,
treatment with monotherapy remains the preferred treatment method, with the use of
polypharmacy reserved as a last resort [53–57].
5. Clinical Studies on Cardiac Events
5.1. Animal Studies
Pre-clinical studies on animals have shown the effect of antipsychotics on the cardiovascular system. One study looked at the effect of risperidone on the cardiac proteomic
signature of mice [59]. The authors found that mice that were exposed to risperidone
for four weeks had differentially expressed proteins in their cardiac tissues, which included proteins associated with mitochondrial respiratory complex I and with pathways
that involved both mitochondrial function and oxidative phosphorylation. In addition,
risperidone altered cardiac mitochondrial oxygen consumption and whole-body energy
expenditure [59].
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5.2. Phase 1
A phase 1, randomized, single-blind, parallel-group study assessed the effects of
high-dose intramuscular injections of ziprasidone and haloperidol on QTc interval prolongation at Tmax . Two doses—20 mg and 30 mg of ziprasidone, or 7.5 mg and 10 mg of
haloperidol—were administered four hours apart to a combined total of 58 patients with
schizoaffective disorder or schizophrenia. The data showed that ziprasidone injections
were associated with mean QTc interval changes (95% CI) from baseline to a lesser degree
than haloperidol—4.6 ms vs. 6.0 ms after the first dose, and 12.8 ms vs. 14.7 ms after the
second dose, respectively. The total doses given in this study were 125% greater than the
recommended dose, yet AEs were mainly mild-to-moderate in severity. The main AE in
the ziprasidone and haloperidol group was somnolence (90.3% vs. 81% respectively). Of
note, extrapyramidal symptoms occurred in one-third of patients in the haloperidol group
compared to 6.5% in the ziprasidone group. No cardiovascular AEs were reported in either
treatment group. No QTc interval exceeded 480 ms in either group, and no changes from
baseline exceeded 60 ms. No patients in the haloperidol group had a QTc greater than 450
msec, whereas two patients in the ziprasidone treatment group experienced QTc greater
than 450 msec (454 and 457 ms). The authors concluded that, at supratherapeutic doses,
both drugs were well tolerated, and QTc interval changes were clinically modest in both
drugs [60].
5.3. Phase 2
A phase 2, multicenter, randomized open-label study evaluated iloperidone-induced
QTc interval changes compared to quetiapine- and ziprasidone-induced changes, in the
absence and presence of metabolic inhibition, among US patients (n = 188). Patients for
this study were diagnosed with schizophrenia or schizoaffective disorder with normal
ECG at baseline. Their usual antipsychotic medication regimes were upheld. Iloperidone,
a D2/5-HT2A antipsychotic, was administered to three different dosing groups: 8 mg
twice daily (BID), 12 mg BID, or 24 mg once daily. Two additional groups received either
80 mg BID ziprasidone or 375 mg BID quetiapine. The medications were allowed to reach
a steady-state. In this instance, steady-state meant that the amount of medication being
absorbed was the same as the amount being cleared from the body, thus allowing the
medication concentrations to stay consistently at the same levels [61]. Steady-state was
reached after two days with quetiapine, between one to three days with ziprasidone, and
between three to four days with iloperidone [62–64]. After the steady-state was reached, a
CYP3A4 inhibitor, called ketoconazole, was administered to the ziprasidone and quetiapine
regimens. Paroxetine, a potent CYP2D6 inhibitor, was administered to those receiving
iloperidone. The iloperidone groups had ketoconazole added to the regimen [65]. The
addition of these CYP 450 inhibitors was to see how the inhibition of the metabolism of
these antipsychotics would affect the QTc interval in patients treated with antipsychotic
polypharmacy.
Without metabolic inhibition, mean changes in QTc in the iloperidone 8 mg BID group
were comparable to the ziprasidone group (8.5–9 ms for the former vs. 9.6 ms for the latter).
The mean QTc for 24 mg QD iloperidone alone was 15 ms. Greater QTc intervals were
observed during the metabolic inhibition periods. Mean QTc increased as the concentration
of iloperidone increased, yet none of these QTc increases were clinically significant, or
≥500 ms. The addition of the metabolic inhibitors with iloperidone during periods 2
(paroxetine) and period 3 (paroxetine and ketoconazole) resulted in greater increases in the
QTc interval [65]. Increased QTc intervals were also observed in individuals with a specific
CYP2D6 polymorphism [65]. Common adverse events with iloperidone included headache,
anxiety, and dyspepsia. Concentration-independent tachycardia occurred without further sequelae, and was mostly mild in those taking iloperidone. One patient receiving
iloperidone 8 mg BID experienced supraventricular tachycardia. The authors concluded
that iloperidone does prolong the QTc interval, but not to the degree that would confer
increased mortality. The authors suggested that QTc interval prolongation may not be the
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optimal measurement for assessing the risk of fatal arrhythmias. Furthermore, baseline QTc
intervals in this study did not predict increased QTc with the antipsychotic drugs used [65].
5.4. Phase 3
The effect on QTc intervals was compared between paliperidone and quetiapine,
two atypical antipsychotics, in a randomized, double-blind, placebo-controlled study. A
total of 109 patients with schizoaffective disorder (21%) or schizophrenia (79%) were
randomized in a 2:2:1 ratio to receive paliperidone extended-release (ER) (starting at
12 mg and increasing to 18 mg supratherapeutic dose), quetiapine (800 mg), or placebo.
Paliperidone ER treatment increased the mean QTc intervals to a modest and similar
degree as quetiapine. The difference between the least squares means that the change from
the baseline population-specific linear-derived correction method (QTcLD) interval was
5.1 ms less with paliperidone ER 12 mg/day than with quetiapine 800 mg/day. No adverse
proarrhythmic events were noted, and no patients experienced a QTcLD greater than 480 ms.
The authors concluded that paliperidone is tolerable at the maximum recommended daily
dose of 12 mg, and is non-inferior to quetiapine [66].
5.5. Phase 4
The ZODIAC trial, a large, phase 4 observational study, evaluated one-year nonsuicide mortality by initiating ziprasidone or olanzapine treatment. The study population
(n = 18,240) had a substantial prevalence of cardiovascular risk factors at baseline, including
18% with hypertension, 14.8% with hyperlipidemia, 46.5% being smokers, 28.9% with a
body mass index greater than or equal to 30 kg/m2 , and 7.8% with diabetes [67]. Nonsuicide mortality and the risk of sudden death were comparable in both groups after a
one-year follow-up [68,69]. The relative risk of cardiovascular mortality for ziprasidone
(N = 3, 0.03%) compared to olanzapine (N = 8, 0.09%) was 0.38 (95% CI = 0.10–1.41). After
expanding the cardiovascular death analysis to include patients with cardiovascular events
with “insufficient data”, the relative risk of cardiovascular mortality for ziprasidone (N = 19,
0.31% of people/year) compared to olanzapine (N = 10, 0.14% of people/year) became
2.12 (95% CI = 0.98–4.55). There was a greater risk of all-cause hospitalizations in the
ziprasidone group. Still, no differences were noted in the risk of hospitalization due to
myocardial infarction, arrhythmia, or arrhythmia reported during hospitalization, between
the treatment groups. The authors noted that, while QTc interval prolongation is associated
with ziprasidone, their study demonstrates that it does not have much clinical significance
compared to olanzapine [68].
Following the initial study and analysis, the data for all-cause mortality were reanalyzed using newly applied ICD-10 codes to explore the sensitivity and specificity of
cardiac-related mortality. The findings with the re-adjudicated death categories were consistent with the initial results. No significant differences were seen between the ziprasidone
and olanzapine populations in all-cause sudden death mortality. The authors noted that,
despite the large sample size, the power of the results is limited because sudden death was
such a rare occurrence. The re-adjudication of the prior results highlights the challenges that
epidemiological studies encounter concerning documenting the timing of out-of-hospital
deaths, and the lack of precision in the hospital documentation [70].
A phase 4, randomized, double-blind, active, and placebo-controlled crossover study
evaluated the effect of inhaled loxapine on QTc in 60 healthy subjects. The results were
validated using moxifloxacin as a positive control. In healthy subjects, two doses of inhaled
loxapine 10 mg, administered two hours apart, was well tolerated, and did not cause
threshold QTc prolongation. AEs aligned with other drug reports, including sedation,
fatigue, dizziness, and somnolence. The authors suggested that inhaled loxapine may be
safer than haloperidol to treat agitation in emergent situations. The authors proposed that
the negligible QTc interval effect may be due to loxapine’s weak blocking effect on the IKr
channel [69].
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A study demonstrated that QTc prolongation was sub-clinical (<500 ms) during a
period of monotherapy, and a period of CYP450 metabolic inhibition, for six antipsychotic
agents. Inpatient subjects underwent a wash-out period from their prescribed antipsychotic, and then were randomized to treatment with either haloperidol (n = 32), ziprasidone
(n = 35), quetiapine (n = 29), olanzapine (n = 28), risperidone (n = 28), or thioridazine
(n = 31). ECGs were taken at baseline, during antipsychotic dose escalation, at steady-state,
and during the metabolic inhibitor phase. All drug groups observed mean increases in
baseline-corrected QTc intervals at the predicted steady-state Cmax. Individual QTc intervals did not exceed 500 ms, even during the concomitant treatment phase with metabolic
inhibitors. The most significant change in mean baseline-corrected QTc interval was observed with thioridazine (30 ms) and the least with olanzapine (1.7 ms); however, the study
was not designed or powered to make statistical associations between the agent groups.
Likewise, although the study was not designed or powered to assess adverse events, no
adverse events were linked with QTc prolongation. A higher incidence of extrapyramidal
side effects was seen in the haloperidol and risperidone groups, compared to the others. A
higher incidence of extrapyramidal side effects was seen in the haloperidol and risperidone
groups, compared to the others [70].
In a large Taiwanese case-crossover study performed from 2000 to 2009, the use of
antipsychotics was associated with a 1.53-fold increased risk of ventricular arrhythmias
(VA) or sudden cardiac death (SCD). The VA/SCD risk was slightly higher among patients taking first-generation antipsychotics (FGAs) when compared to second-generation
antipsychotics (SGAs) (adjusted OR (AOR) = 1.66, 95% CI = 1.43–1.91 for FGAs; AOR
= 1.36, 95% CI = 1.20–1.54 for SGAs) and the female gender. The risk of VA/SCD was
higher for those on antipsychotic medications for a short duration, defined as seven days
or less. Antipsychotics with IKr potassium channel blocking activity were associated with
a 1.24-fold greater risk of VA/SCD. The authors concluded that SGAs may be safer than
FGAs with respect to VA/SCD risk, and that they must be prescribed carefully during the
first phase of treatment [71].
5.6. Other Studies
Of the 16 that enrolled, ten men with schizophrenia completed an open-label subchronic olanzapine treatment. They were monitored during their sleep for heart rate
variability, QTc interval, and EEG activity, the latter of which was taken to verify that the
patients were asleep. Baseline measurements of heart rate variability and ECG were taken,
and no severe adverse events occurred. Baseline sleep stages matched conditions in healthy
subjects (i.e., with no schizophrenia). During olanzapine treatment, a small but significant
shift towards enhanced sympathetic tone was observed. A statistically significant increase
in mean heart rate during olanzapine treatment compared to baseline was observed as
expected, but was not clinically significant. The findings of this study are consistent with
others documenting olanzapine’s cardiac profile. Olanzapine may increase heart rate,
but it reduces heart rate variability in patients with schizophrenia compared to control
treatment [71].
An observational study compared the QTc interval for antipsychotic monotherapy with
that for polypharmacological treatment [58]. The subjects were patients with schizophrenia
from an outpatient clinic in Denmark. Sixty-five patients had electrocardiograms available
for analysis, of which 65% had QTc prolongation. The authors found no difference in the QTc
interval between patients on antipsychotic monotherapy and those receiving antipsychotic
polypharmacological treatment. The authors also found that women presented with a
longer QTc interval when receiving polypharmacy than on monotherapy (p = 0.01) [58].
Table 2 provides a summary of the clinical studies discussed in this section.
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Table 2. Clinical Trials Summary.
Author (Year)

Groups Studied and Intervention

Results and Key Findings

Conclusions

Miceli et al., 2010

Phase 1, randomized, single-blind,
parallel-group comparison of QTc
interval change following
intramuscular injection of 125%
greater than daily recommended
dose of ziprasidone and haloperidol
among 58 patients with
schizoaffective disorder or
schizophrenia

No QTc interval exceeded 480 msec in
either group, and no changes from
baseline exceeded 60 ms
AEs were mostly mild-to-moderate in
severity

At supratherapeutic doses, both
drugs were well tolerated and
QTc interval changes were
clinically modest in both drugs

Potkin et al., 2013

Phase 2, multicenter, randomized,
open-label study evaluating
iloperidone with respect to QTc
interval changes in comparison to
quetiapine and ziprasidone in the
context of metabolic inhibition
among 188 patients with
schizoaffective disorder or
schizophrenia

Without metabolic inhibition, mean
changes in QTc in the iloperidone 8 mg
BID group were comparable to the
ziprasidone group
The mean QTc for 24 mg QD iloperidone
alone was 15 ms
Mean QTc increased as concentration of
iloperidone increased, yet none were
clinically significant, or ≥500 ms
Concentration-independent tachycardia
occurred without further sequelae and
was mostly mild in those taking
iloperidone

The authors suggested that QTc
interval prolongation may not be
the optimal measurement for
assessing risk of fatal arrhythmias
Baseline QTc intervals in this
study did not predict increased
QTc with the antipsychotic drugs
used in this study

Hough et al., 2011

Phase 3, randomized, double-blind,
placebo-controlled study evaluating
the effect of paliperidone and
quetiapine on QTc intervals in
109 patients with schizoaffective
disorder (21%) or schizophrenia
(79%)

Paliperidone extended-release treatment
increased the mean QTc intervals to a
modest and similar degree as quetiapine

The authors concluded that
paliperidone is tolerable at the
maximum recommended daily
dose of 12 mg and is non-inferior
to quetiapine

Strom et al., 2011

The ZODIAC trial
Phase 4 trial where either
ziprasidone or olanzapine treatment
was initiated

There was a greater risk of all-cause
hospitalizations in the ziprasidone group,
but no differences were noted in the risk of
hospitalization due to myocardial
infarction, arrhythmia, or arrhythmia
reported during hospitalization between
the treatment groups

Authors noted that while QTc
interval prolongation is associated
ziprasidone, evidence from their
study demonstrates that it does
not have a great deal of clinical
significance with respect to
cardiovascular events or death
when compared to olanzapine

Cassella et al., 2015

Phase 4, randomized, double-blind,
active, and placebo-controlled
crossover study evaluating the
effect of inhaled loxapine on QTc in
60 healthy subjects
Moxifloxacin served as a positive
control to validate the results

Two doses of inhaled loxapine 10 mg
administered 2 h apart were well tolerated
and did not cause threshold QTc
prolongation

The authors suggested that
inhaled loxapine may be safer
than haloperidol to treat agitation
in emergent situations.

Harrigan et al., 2004

A prospective, randomized,
parallel-group study evaluating QTc
prolongation associated with
monotherapy with the following
drugs: haloperidol (n = 32),
ziprasidone (n = 35), quetiapine
(n = 29), olanzapine (n = 28),
risperidone (n = 28), thioridazine
(n = 31),
followed by co-administration of
drug and metabolic inhibitor

QTc prolongation was sub-clinical
(<500 ms) during monotherapy and
co-administration with CYP450 inhibitors
The greatest change in mean
baseline-corrected QTc interval was
observed with thioridazine (30 ms) and
least with olanzapine (1.7 ms)

Inhibition of the CYP450 pathway
did not result in large increases in
Cmax or QTc intervals, suggesting
that an unidentified metabolic
pathway plays a role in the
metabolism of these antipsychotic
agents
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Table 2. Cont.
Author (Year)

Groups Studied and Intervention

Results and Key Findings

Conclusions

Wu et al., 2015

A large (n = 17,718) Taiwanese
case-crossover study performed
from 2000 to 2009 assessing the risk
of ventricular arrhythmia (VA) and
sudden cardiac death (SCD)
resulting from the use of
antipsychotics

The use of antipsychotics was associated
with a 1.53-fold increased risk of VA/ SCD
VA/SCD risk was slightly higher among
patients taking first-generation
antipsychotics (FGA) than
second-generation antipsychotics (SGA)
and female gender
Antipsychotics with human
ether-à-go-go-related gene (hERG)
potassium channel blocking activity were
associated with 1.24-fold greater risk of
VA/SCD

The authors concluded that SGA
may be safer than FGA with
respect to VA and SCD risks, and,
importantly, they must be
prescribed carefully during the
first phase of treatment

Mann et al., 2004

Men with schizophrenia (n = 10)
completed an open-label
sub-chronic olanzapine treatment,
and were monitored during their
sleep for heart rate variability, QTc
interval, and EEG activity

Baseline sleep stages matched conditions
in healthy subjects with no schizophrenia
During olanzapine treatment, a small but
significant shift towards enhanced
sympathetic tone was observed

Olanzapine may increase heart
rate, but it reduces heart rate
variability in patients with
schizophrenia compared to
control treatment

Elliot et al., 2018

Observational study of patients
with schizophrenia in Denmark
65 patients in the study had EKGs
available for analysis for QTc
Interval

No differences were seen between
monotherapy and polypharmacological
treatment
65% overall had a prolonged QTc
Women had a longer QTc interval than
men on polypharmacological treatment
than on monotherapy

When polypharmacy is used,
women may be more at risk of a
prolonged QTc interval

6. Conclusions
In the present investigation, antipsychotic polypharmacy was evaluated for its potential to mediate or modulate QTc changes and/or sudden cardiac death. QTc prolongation
and sudden cardiac death exist in patients taking antipsychotic monotherapy. The risk
likely increases for concomitant use of specific drugs that prolong the QTc interval, such as
opioids, antibiotics, and illicit drugs. However, to date, little evidence exists in the literature
to indicate antipsychotic polypharmacy has an increased mortality rate when compared to
antipsychotic monotherapy. This is likely related to the fact that many clinical studies were
performed before FDA approval, which are typically monotherapy in direct comparison to
real-life, commonplace polypharmacy regimens.
In this regard, the literature demonstrates that QTc intervals may not be adequate
predictors of sudden cardiac death. Lethal arrhythmias from QTc-prolonging agents are
additive and/or synergistic. Therefore, theoretically combining these diverse agents with
known risk factors, such as hypokalemia, advanced age, and the female gender; cardiovascular risk factors, including obesity, hyperlipidemia, nicotine use, and insulin resistance,
would increase the potential risk of morbidity and mortality. Age and postmenopausal
status can also play a role in antipsychotic adverse effects in general. Older patients are
more sensitive to the adverse effects of antipsychotics due to changes in their ability to
metabolize drugs. Post-menopausal patients may experience the need for increasing doses
of antipsychotics due to the increase in psychotic symptoms that can be seen once estrogen
levels drop. This can lead to more adverse effects in general, since the dose is higher.
In summary, to date, many studies are at best inconclusive with regards to the coadministration of other drugs, including known QTc-prolonging agents. Prescribers should
be vigilant, considering each associated risk factor as well as the additive and/or synergistic effects. Most literature describes three or more conditions and/or drugs that are
QTc-prolonging agents that significantly increase the risk for sudden death. Additional
research more precisely evaluating drug–drug interactions and the related risk factors, as
well as real-life utilization and clinical outcomes, are warranted given the commonplace
practice of antipsychotic polypharmacy before best practices can be determined.
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